• Follow the Money: MD Anderson’s High-Affinity Monoclonal Antibody Research, New Neurodegeneration Research Center, More

    Clinical Research News | Funding for microbial resistance and infectious disease research, tracking Long COVID in diverse pediatric and adult populations, an AI-powered platform that identifies novel cancer therapies and predicts the efficacy of cancer drug combinations, and more.

    Dec 22, 2022

  • ClinEco Helps Trial Stakeholders ‘Cut Through The Noise’ To Find One Another

    Clinical Research News | The world’s first B2B market network for clinical trials is now fully functioning and onboarding, as well as learning, from early adopters. ClinEco recently moved into the open beta stage of its development with a gratifyingly diverse mix of stakeholders registering for free membership.

    Dec 20, 2022

  • Insilico Medicine’s AI-Driven Platform Pushes The Envelope Of Drug Discovery

    Clinical Research News | During a recent virtual unveiling party livestreamed from around the world, Insilico Medicine introduced the latest updates to Pharma.AI, its end-to-end drug discovery platform using generative artificial intelligence to discover new targets, design new molecules, and predict the outcome of clinical trials. Among the highlights were the addition of a knowledge graph to target discovery product PandaOmics and numerous new panels to generative chemistry engine Chemistry42.

    Dec 15, 2022

  • In Virtual Trials, Two Alzheimer’s Drugs Do Poor Job Of Slowing Cognitive Decline

    Clinical Research News | Researchers from Duke, Penn State, and the University of Tennessee collaboratively built a mathematical model of Alzheimer’s disease that used real, de-identified patient data to simulate health outcomes from a pair of anti-amyloid-beta drugs. Notably, the virtual (aka in silico) clinical trials employed a computational approach that provides “individualized prescriptions” based on optimal timing and dosing of treatment while minimizing possible side effects.

    Dec 14, 2022

  • In Virtual Trials, Two Alzheimer’s Drugs Do Poor Job Of Slowing Cognitive Decline

    Clinical Research News | Researchers from Duke, Penn State, and the University of Tennessee collaboratively built a mathematical model of Alzheimer’s disease that used real, de-identified patient data to simulate health outcomes from a pair of anti-amyloid-beta drugs. Notably, the virtual (aka in silico) clinical trials employed a computational approach that provides “individualized prescriptions” based on optimal timing and dosing of treatment while minimizing possible side effects.

    Dec 14, 2022